Notwithstanding promising clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant resistance from pharmacy benefit managers. Such insurers are https://margieglzm305521.snack-blog.com/42251724/company-s-vyndamax-faces-is-dealing-with-pbm-obstacles-a-look-of-access-battles